Merck, Daiichi Sankyo Pull NSCLC Filing for ADC, Citing Underwhelming Survival Findings

Patritumab deruxtecan was unable to significantly improve overall survival in patients with locally advanced or metastatic non-small cell lung cancer with EGFR mutations.